Hematology/oncology clinics of North America
-
Hematol. Oncol. Clin. North Am. · Dec 1989
Randomized Controlled Trial Clinical TrialSystemic therapy in resectable breast cancer.
There is now convincing evidence that adjuvant systemic therapy for high-risk breast cancer can significantly reduce tumor mortality at 5 years. The overall treatment benefit for women with node-positive tumors may be considered moderate but clinically important. ⋯ Primary (neoadjuvant) chemotherapy can allow conservative surgery in most tumors suitable for mastectomy, but this form of treatment remains, at present, experimental. Potential long-term toxicity from systemic adjuvant therapy should be continuously monitored.